Bristol-Myers Squibb Archives -

Abecma hits the mark in earlier-stage multiple myeloma

Phil Taylor 2seventy bio, Abecma, Bristol-Myers Squibb, CAR-T therapies, Carvykti, immuno-oncology, Johnson & Johnson, multiple myeloma, Oncology 0 Comment

Bristol-Myers Squibb is on course to move its BCMA-targeting CAR-T therapy further up the treatment pathway in multiple

Abecma hits the mark in earlier-stage multiple myeloma

https://pharmaphorum.com/news/abecma-hits-the-mark-in-earlier-stage-multiple-myeloma/

News/ News/ R&D

BMS adds to IBD pipeline with $1.9bn GentiBio deal

Phil Taylor Bristol-Myers Squibb, deucravacitinib, GentiBio, Immunology and inflammation, inflammatory bowel disease, partnering, Treg, Zeposia 0 Comment

Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for

BMS adds to IBD pipeline with $1.9bn GentiBio deal

https://pharmaphorum.com/news/bms-adds-to-ibd-pipeline-with-1-9bn-gentibio-deal/

Digital/ Oncology/ R&D/ Views & Analysis/ Views & Analysis/ Views & Analysis/ Views and analysis

AI tissue analysis enables rapid discovery of drug candidates

Ben Hargreaves AI, AI drug discovery, Bristol-Myers Squibb, drug discovery, exscientia, Owkin, Sanofi 0 Comment

AI could address the most significant issue in drug discovery, finds Ben Hargreaves, and also offers the potential

AI tissue analysis enables rapid discovery of drug candidates

https://pharmaphorum.com/digital/ai-tissue-analysis-enables-rapid-discovery-of-drug-candidates/

News/ News/ News/ Oncology/ R&D

BMS’ plan to move Opdivo into adjuvant RCC gets knocked back

Phil Taylor adjuvant, Bristol-Myers Squibb, immuno-oncology, Oncology, Opdivo, renal cell carcinoma 0 Comment

Bristol-Myers Squibb has revealed that its checkpoint inhibitor combination of Opdivo and Yervoy failed a phase 3 trial

BMS’ plan to move Opdivo into adjuvant RCC gets knocked back

https://pharmaphorum.com/news/bms-plan-to-move-opdivo-into-adjuvant-rcc-gets-knocked-back/

News/ News/ News/ Oncology/ Sales and Marketing

Opdualag off to a flying start, says BMS CEO

Phil Taylor Bristol-Myers Squibb, Financial, immuno-oncology, melanoma, Oncology, Opdualag 0 Comment

Bristol-Myers Squibb’s new immune checkpoint inhibitor combination Opdualag has only been on the US market for a few

Opdualag off to a flying start, says BMS CEO

https://pharmaphorum.com/news/opdualag-off-to-a-flying-start-says-bms-ceo/

Market Access/ News/ News/ News/ Oncology

Roche’s fast-growing eye drug Vabysmo set for EU approval

Phil Taylor Alnylam Pharmaceuticals, Amvuttra, AstraZeneca, Bristol-Myers Squibb, CHMP, Eli Lilly, Eylea, Mounjaro, Opdualag, ophthalmology, Roche, Tezspire, Vabysmo 0 Comment

Roche has been trumpeting the rapid uptake of its new eye disease drug Vabysmo as it takes on

Roche’s fast-growing eye drug Vabysmo set for EU approval

https://pharmaphorum.com/news/roches-fast-growing-eye-drug-vabysmo-set-for-eu-approval/

Market Access/ News/ News

BMS’ Opdivo gets NHS use as adjuvant bladder cancer therapy

Phil Taylor access, Bristol-Myers Squibb, HEOR, NHS, NICE, Opdivo, UK, urothelial carcinoma 0 Comment

NICE has recommended routine use of Bristol-Myers Squibb’s Opdivo for the adjuvant treatment of some patients with urothelial

BMS’ Opdivo gets NHS use as adjuvant bladder cancer therapy

https://pharmaphorum.com/news/bms-opdivo-gets-nhs-use-as-adjuvant-bladder-cancer-therapy/

News/ News/ News/ Oncology/ R&D

Novartis eyes earlier use of PD-1 drug in oesophageal cancer

Phil Taylor BeiGene, Bristol-Myers Squibb, immuno-oncology, Keytruda, Merck & Co, Novartis, oesophageal cancer, Oncology, Opdivo, tislelizumab 0 Comment

Novartis is still waiting for FDA approval of its PD-1/PD-L1 inhibitor latecomer tislelizumab in relapsed oesophageal cancer, but

Novartis eyes earlier use of PD-1 drug in oesophageal cancer

https://pharmaphorum.com/oncology/novartis-eyes-earlier-use-of-pd-1-drug-in-oesophageal-cancer/

News/ News/ News/ Oncology/ R&D

AZ takes aim at BMS’ lead in neoadjuvant NSCLC

Phil Taylor AstraZeneca, Bristol-Myers Squibb, Imfinzi, immuno-oncology, Keytruda, Merck & Co, Non-small cell lung cancer, Oncology, Opdivo 0 Comment

Just weeks after Bristol-Myers Squibb claimed an FDA green light for Opdivo as a neoadjuvant therapy for non-small

AZ takes aim at BMS’ lead in neoadjuvant NSCLC

https://pharmaphorum.com/news/az-takes-aim-at-bms-lead-in-neoadjuvant-nsclc/

Trending

Bristol-Myers Squibb

Login